Continued access to remibrutinib: safety monitoring for up to 3 years
NCT ID NCT07456891
First seen Mar 10, 2026 · Last updated May 08, 2026 · Updated 10 times
Summary
This study offers continued treatment with remibrutinib to about 212 people who have already completed a Novartis-sponsored remibrutinib study and are benefiting from the drug. The main goal is to monitor long-term safety over up to three years. Participants must have a dermatological or allergy condition and cannot access remibrutinib outside of a clinical trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDICATION OF THE PARENT PROTOCOL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGLondon, Ontario, N6H 5L5, Canada
Conditions
Explore the condition pages connected to this study.